NEO
NEOGENOMICS INC
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$16.84
+2.12%Price chart
Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3Nov 6
Key dataNov 6, 2026
Open$16.85
From 52W high−15.42%
Volume1.31M
Market cap$2.18B
P/E (TTM)—
P/S (TTM)2.8x
Div yield—
Key dataNov 6, 2026
Open
$16.85
From 52W high
−15.42%
Volume
1.31M
Market cap
$2.18B
ValuationView details →
P/E (Fwd)
58.4x
EV/EBITDA
77.1x
P/E (TTM)
—
RSI (14)
44.0
MomentumView details →
1D Return
+2.12%
YTD Return
+39.46%
SummaryUpdated Sep 1, 2026
NeoGenomics, Inc. (NASDAQ:NEO) is a specialized cancer diagnostic testing company founded in 2001 and headquartered in Fort Myers, Florida. The company went public in 2004 and has since evolved into one of the leading providers of cancer-focused laboratory testing services in the United States. NeoGenomics operates a network of testing laboratories across the U.S., Europe, and Asia, serving hospitals, pathologists, oncologists, and pharmaceutical companies. The company has undergone significant strategic transformation in recent years, focusing on advanced genomic testing technologies and expanding its commercial presence in community oncology markets.
Similar companies
Latest newsMore news →
NeoGenomics reported third-quarter 2026 revenue of $209.254 million, up 11.4% year over year, and a net loss of $7.546 million.10d agoNEOGENOMICS INC expanded its partnership with Indica Labs, Inc. to scale AI-powered digital pathology and support more timely, consistent diagnostic insights.23d agoNEOGENOMICS INC said it will report its third-quarter 2026 financial results after the U.S. market close on October 28, 2026.24d ago